CTOs on the Move

ReAlta Life Sciences

www.realtalifesciences.com

 
ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

ReAlta Life Sciences raised $14M on 04/21/2020
ReAlta Life Sciences raised $20M on 04/28/2021

Similar Companies

Nano-C

Nano-C is a Westwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Diagnostics Center

DNA Diagnostics Center is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stolle Milk Biologics Inc

Stolle Milk Biologics Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Chiasma

Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.